Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Summary:
- MACD is crossing MACD signal line at 0.1. MACD crossing signal line is bullish signal.
| MarketCap | 2.2B |
|---|---|
| PE Ratio | -28.6 |
| PEG Ratio | 21.2 |
| P/B | 2.5 |
| P/S (ttm) | 3.6 |
| Earning Growth (QoQ) | |
| Revenue Growth (QoQ) | |
| Short % | 10% |
| Held by Institutions % | 100% |
| 1 Day Vol Adjusted Return | 1.4 |
| 1 Month Vol Adjusted Return | 0.8 |
| 3 Month Vol Adjusted Return | -4.0 |
| 6 Month Vol Adjusted Return | -2.4 |
| 20 Days SMA Price ZScore | 1.2 |
| 50 Days SMA Price ZScore | 0.3 |
| 12 -26 Days PPO | -0.5 |
| 1 Month Average Short Volume Ratio | 68.1 |
| 1 Day Volume Change ZScore | -0.2 |
| 1 Month Daily Vol | 3.6 |
Stock news
SALT LAKE CITY, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will provide an update on the execution of the company’s strategic transformation and growth plans at the 40th Annual J.P. Morgan Health Care Conference at 2:15 p.m. ET on Jan. 11, 2022. Diaz will discuss the growing role of genetic insights in context with industry trends, new commercial capabilities and products that advance he
Nationwide search for permanent successor underwaySALT LAKE CITY, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the retirement of Jerry Lanchbury Ph.D. as chief scientific officer (CSO), after more than 19 years of distinguished service. A national search for a permanent CSO is underway. Lanchbury will provide consulting and scientific advisory services for Myriad Genetics through the end of the first
Investors are optimistic about Myriad Genetics (MYGN), given robust volume growth for GeneSight and prenatal testing.
SALT LAKE CITY, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Now is the time when people start to think of new year’s resolutions to improve their health. For many, the focus is on physical goals like losing weight or exercising more. A nationwide survey suggests that many may want to consider adding mental health resolutions to their list. More than three out of four respondents said that physical and mental health were equally important. Yet, when it comes to care, four in 10 indicate they’re more likely
GeneSight Mental Health Monitor finds many parents struggle to know the difference between teenage behavior and a mental health challengeSALT LAKE CITY, Dec. 15, 2021 (GLOBE NEWSWIRE) -- One of the biggest issues parents of teenagers may face is determining if their child is experiencing a mental health challenge or ordinary “growing pains.” Only half of parents* with children ages 16 to 24 said they are very or completely confident they can tell the difference between normal adolescent challeng
SALT LAKE CITY, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the promotion of Nicole Lambert to chief operating officer (COO). In her new role, she will continue to report directly to Paul J. Diaz, president and CEO, Myriad Genetics. Over a 20-year career at the company, Lambert served in several senior leadership positions, most recently overseeing Myriad’s Oncology, Women’s Health and International
SALT LAKE CITY, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two upcoming poster presentations at the 2021 San Antonio Breast Cancer Symposium (SABCS) that showcase the importance of genetic testing and precision medicine as integral components of both breast cancer treatment recommendations and risk assessment. “These studies demonstrate our ongoing commitment to excellence in scientific research and
Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment drove Q3 sales despite a challenging business environment.